Juette, Hendrik, Reike, Moritz, Wirtz, Ralph M., Kriegmair, Maximilian, Erben, Philipp, Tully, Karl, Weyerer, Veronika, Eckstein, Markus, Hartmann, Arndt, Eidt, Sebastian ORCID: 0000-0003-0891-1936, Wezel, Felix, Bolenz, Christian, Tannapfel, Andrea, Noldus, Joachim and Roghmann, Florian (2021). KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. J. Pers. Med., 11 (6). BASEL: MDPI. ISSN 2075-4426

Full text not available from this repository.

Abstract

Patients with muscle-invasive bladder cancer (MIBC) that underwent neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) show improved overall survival, especially those with pathological complete response (pCR). The response to NAC according to molecular subtypes has been discussed. Molecular targets such as estrogen receptor (ESR1) and human epidermal growth factor receptor 2 (ERBB2) play an important role in breast cancer management and have also been associated with urothelial bladder cancer. Hence, the association of Keratin 20 (KRT20) Keratin 5 (KRT5), ESR1, and ERBB2 mRNA expression in MIBC at transurethral resection (TUR-BT) with pCR after NAC was analyzed retrospectively. Formalin-fixed paraffin-embedded tumour tissue samples from TUR-BT of 54 patients (42 males, 12 females, median age of 64) with MIBC were analyzed for KRT20, KRT5, ESR1, and ERBB2 mRNA expression. After NAC, RC was performed, and the specimens were evaluated for pCR. Statistical analyses comprised nonparametric and chi(2) testing, partition models, and Spearman correlation analyses. After NAC, 22 out of 54 patients (40.7%) had pCR. Tumours with an elevated expression of markers associated with luminal differentiation (KRT20, ERBB2, ESR1) were associated with a higher chance of pCR (55% vs. 15.8%, p = 0.009). Elevated ERBB2 expression was positively correlated with luminal expression features such as KRT20, and negatively with basal characteristics such as KRT5. Patients with MIBC showing a high expression of ERBB2, ESR1, or KRT20 have a significantly higher chance of pCR following NAC. These findings might improve patient selection for NAC in MIBC.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Juette, HendrikUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Reike, MoritzUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wirtz, Ralph M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kriegmair, MaximilianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Erben, PhilippUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tully, KarlUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Weyerer, VeronikaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eckstein, MarkusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hartmann, ArndtUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eidt, SebastianUNSPECIFIEDorcid.org/0000-0003-0891-1936UNSPECIFIED
Wezel, FelixUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bolenz, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tannapfel, AndreaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Noldus, JoachimUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Roghmann, FlorianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-595022
DOI: 10.3390/jpm11060473
Journal or Publication Title: J. Pers. Med.
Volume: 11
Number: 6
Date: 2021
Publisher: MDPI
Place of Publication: BASEL
ISSN: 2075-4426
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
MESSENGER-RNA-EXPRESSION; METASTATIC UROTHELIAL CARCINOMA; TRASTUZUMAB; SUBTYPES; RESISTANCE; PLATINUM; GRADE; STAGE; HER2; PGRMultiple languages
Health Care Sciences & Services; Medicine, General & InternalMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/59502

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item